Rachael Easton

Rachael Easton has extensive experience in the field of clinical development and pharmacology. Rachael currently holds the position of Vice President and Head of Clinical Development at Cogent Biosciences since 2022. Prior to this, they worked at GSK as the Group Senior Medical Director, Clinical Development Lead from 2019 to 2022. During their time at GSK, they also served as the Medical Director in the Immuno-Oncology Combinations Research Unit from 2019 to 2022.

Before joining GSK, Easton worked at Immunocore as the Executive Director of Clinical Development from 2017 to 2019. Rachael was also associated with Sanofi for four years, from 2013 to 2017, where they held the position of Senior Director of Translational Medicine & Clinical Pharmacology.

In their earlier career, Easton gained experience at CSL Behring as the Director of Clinical Pharmacology from 2011 to 2013. Prior to that, they worked at sanofi-aventis in various roles, including Senior Director, Director, and Associate Director of Clinical and Exploratory Pharmacology from 2007 to 2011.

Easton started their professional journey at the University of Pennsylvania School of Medicine as an Instructor from 2005 to 2007. Rachael then completed their fellowship in Endocrinology, Diabetes, & Metabolism at the University of Pennsylvania Health System from 2001 to 2005, following their tenure as a house staff in Internal Medicine from 1999 to 2001.

Overall, Easton has had a diverse range of roles and responsibilities throughout their career in the pharmaceutical and medical fields, demonstrating their expertise in clinical development, pharmacology, and translational medicine.

Rachael Easton completed their education at the Washington University School of Medicine in St. Louis from 1992 to 1999. Rachael obtained an M.D./Ph.D. degree with a focus on Medicine and Molecular Cell Biology. Additionally, Rachael Easton has obtained board certifications in Endocrinology, Diabetes, and Metabolism from the American Board of Internal Medicine in 2014, as well as board certification in Internal Medicine in 2012.